Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor end result of sufferers with COVID-19 after CAR T-cell remedy for B-cell malignancies: outcomes of a multicenter research on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Illnesses Working Get together and the European Hematology Affiliation (EHA) Lymphoma Group. Leukemia. 2021;35:3585–8.
Busca A, Salmanton-García J, Corradini P, Marchesi F, Cabirta A, Di Blasi R, et al. COVID-19 and CAR T cells: a report on present challenges and future instructions from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv. 2022;6:2427–33.
Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Safety and waning of pure and hybrid immunity to SARS-CoV-2. N. Engl J Med. 2022;386:2201–12.
Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2 reinfections: overview of efficacy and length of pure and hybrid immunity. Environ Res. 2022;209:112911.
Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak Ok, Møller CH, et al. Family transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark. Nat Commun. 2022;13:5760.
Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 omicron variant. N Engl J Med. 2022;17:386.e14
Ljungman P, Tridello G, Piñana JL, Ciceri F, Sengeloev H, Kulagin A, et al. Improved outcomes over time and better mortality in CMV seropositive allogeneic stem cell transplantation sufferers with COVID-19; An infectious illness working occasion research from the European Society for Blood and Marrow Transplantation registry. Entrance Immunol. 2023;14:1125824.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al. Actual-world evaluation of immunogenicity in immunocompromised people following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the possible scientific trial COVAXID. EBioMedicine. 2023;94:104700.
Haggenburg S, Hofsink Q, Rutten CE, Nijhof IS, Hazenberg MD, Goorhuis A. SARS-CoV-2 vaccine-induced humoral and mobile immunity in sufferers with hematologic malignancies. Semin Hematol. 2022;59:192–7.
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, et al. COBRA KAI Research Crew. Antibody Response in Immunocompromised Sufferers With Hematologic Cancers Who Acquired a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19. JAMA Oncol. 2022;8:1477–83.
Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, et al. Response to SARS-CoV-2 vaccination in sufferers after hematopoietic cell transplantation and CAR T-cell remedy. Blood. 2021;138:1278–81.
Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, et al. Replace of suggestions for the administration of COVID-19 in sufferers with haematological malignancies, haematopoietic cell transplantation and CAR T remedy, from the 2022 European Convention on Infections in Leukaemia (ECIL 9). Leukemia. 2023;37:1933–8.
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Administration of adults and kids receiving CAR T-cell remedy: 2021 finest apply suggestions of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Affiliation (EHA). Ann Oncol. 2022;33:259–75.
Pagano L, Salmanton-García J, Marchesi F, Blennow O, Gomes da Silva M, Glenthøj A, et al. Breakthrough COVID-19 in vaccinated sufferers with hematologic malignancies: outcomes from the EPICOVIDEHA survey. Blood. 2022;140:2773–87.
van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al. Affect of SARS-CoV-2 vaccination and monoclonal antibodies on end result post-CD19-directed CAR T-cell remedy: an EPICOVIDEHA survey. Blood Adv. 2023;7:2645–55.
McNerney KO, Richards RM, Aguayo-Hiraldo P, Calkoen FG, Talano JA, Moskop A, et al. SARS-CoV-2 infections in pediatric and younger grownup recipients of chimeric antigen receptor T-cell remedy: a world registry report. J Immunother Most cancers. 2023;11:e005957.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Medical course and threat elements for mortality of grownup inpatients with COVID-19 in wuhan, China: A retrospective cohort research. Lancet 2020;395:1054–62.
Hughes TD, Subramanian A, Chakraborty R, Cotton SA, Herrera M, Huang Y, et al. The impact of SARS-CoV-2 variant on respiratory options and mortality. Sci Rep. 2023;13:4503.
Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative evaluation of the dangers of hospitalisation and dying related to SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort research. Lancet. 2022;399:1303–12.
Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, et al. Fourth mRNA COVID-19 vaccination in immunocompromised sufferers with haematological malignancies (COBRA KAI): a cohort research. EClinicalMedicine. 2023;61:102040.
Müller TR, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, et al. Additive results of booster mRNA vaccination and SARS-CoV-2 Omicron an infection on T cell immunity throughout immunocompromised states. Sci Transl Med. 2023;15:eadg9452.
Gonzalez MA, Bhatti AM, Fitzpatrick Ok, Boonyaratanakornkit J, Huang ML, Campbell VL, et al. Humoral and mobile responses to SARS-CoV-2 vaccines earlier than and after chimeric antigen receptor-modified T-cell remedy. Blood Adv. 2023;7:1849–53.
Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, et al. Vaccine-induced T-cell responses towards SARS-CoV-2 and its Omicron variant in sufferers with B cell-depleted lymphoma after CART remedy. Blood. 2022;140:152–6.
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in sufferers with COVID-19 and hematologic most cancers. Nat Med. 2021;27:1280–9.
Khawaja F, Papanicolaou G, Dadwal S, Pergam SA, Wingard JR, Boghdadly ZE, et al. Regularly Requested Questions on Coronavirus Illness 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Mobile Remedy and the American Society of Hematology. Transpl Cell Ther. 2023;29:10–18.
Kampouri E, Hill JA, Dioverti V. COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell remedy. Transpl Infect Dis. 2023;25:e14144.
Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and important for survival. Nat Commun. 2021;12:2670.
Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Security, tolerability and viral kinetics throughout SARS-CoV-2 human problem in younger adults. Nat Med. 2022;28:1031–41.
Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, et al. Triple mixture remedy with 2 antivirals and monoclonal antibodies for persistent or relapsed extreme acute respiratory syndrome coronavirus 2 an infection in immunocompromised sufferers. Clin Infect Dis. 2023;77:280–6.
Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, et al. Profitable remedy of extended, extreme coronavirus illness 2019 decrease respiratory tract illness in a B cell acute lymphoblastic leukemia affected person with an prolonged course of Remdesivir and Nirmatrelvir/Ritonavir. Clin Infect Dis. 2023;76:926–9.
Brown LK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al. Therapy of persistent or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022;149:557–61.
